When.com Web Search

  1. Ads

    related to: other drugs comparable to jardiance for diabetes treatment

Search results

  1. Results From The WOW.Com Content Network
  2. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

  3. Empagliflozin - Wikipedia

    en.wikipedia.org/wiki/Empagliflozin

    In clinical trials, participants with type 2 diabetes taking empagliflozin with other diabetic medications lost an average of 2% of their baseline body weight. [55] [56] A higher percentage of people taking empagliflozin achieved weight loss greater than 5% from their baseline, which has been associated with improved glucose control.

  4. Mounjaro vs. Ozempic: Which One Is Best for Me to Try for ...

    www.aol.com/mounjaro-vs-ozempic-one-best...

    In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

  5. Biden targets diabetes drug Jardiance, blood thinner Eliquis ...

    www.aol.com/finance/biden-targets-diabetes-drug...

    The diabetes treatments Jardiance from Eli Lilly and Co. and Merck's Januvia made the list, along with Amgen’s autoimmune disease treatment Enbrel. Other drugs include Entresto from Novartis ...

  6. These Diabetes Drugs Could Help Lower Your Risk of ... - AOL

    www.aol.com/lifestyle/diabetes-drugs-could-help...

    According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood ...

  7. Meglitinide - Wikipedia

    en.wikipedia.org/wiki/Meglitinide

    A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.

  1. Ads

    related to: other drugs comparable to jardiance for diabetes treatment